JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentros

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónReglamento de ciencia abierta de la UMAPolítica de RIUMAPolitica de datos de investigación en RIUMASHERPA/RoMEODulcinea
    Preguntas frecuentesManual de usoDerechos de autorContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Biología Molecular y Bioquímica - (BMB)
    • BMB - Artículos
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Biología Molecular y Bioquímica - (BMB)
    • BMB - Artículos
    • Ver ítem

    Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway

    • Autor
      García-Caballero, Melissa; Blacher, S.; Pauper, J.; Quesada, Ana R.; Medina, Miguel ÁngelAutoridad Universidad de Málaga; [et al.]
    • Fecha
      2016
    • Editorial/Editor
      Wiley
    • Palabras clave
      Antiangiogénicos
    • Resumen
      BACKGROUND AND PURPOSE Lymphangiogenesis is an important biological process associated with the pathogenesis of several diseases, including metastatic dissemination, graft rejection, lymphoedema and other inflammatory disorders. The development of new drugs that block lymphangiogenesis has become a promising therapeutic strategy. In this study, we investigated the ability of toluquinol, a 2-methyl-hydroquinone isolated from the culture broth of the marine fungus Penicillium sp. HL-85-ALS5-R004, to inhibit lymphangiogenesis in vitro, ex vivo and in vivo. EXPERIMENTAL APPROACH We used human lymphatic endothelial cells (LECs) to analyse the effect of toluquinol in 2D and 3D in vitro cultures and in the ex vivo mouse lymphatic ring assay. For in vivo approaches, the transgenic Fli1:eGFPy1 zebrafish, mouse ear sponges and cornea models were used. Western blotting and apoptosis analyses were carried out to search for drug targets. KEY RESULTS Toluquinol inhibited LEC proliferation,migration, tubulogenesis and sprouting of new lymphatic vessels. Furthermore, toluquinol induced apoptosis of LECs after 14 h of treatment in vitro, blocked the development of the thoracic duct in zebrafish and reduced the VEGF-C-induced lymphatic vessel formation and corneal neovascularization in mice. Mechanistically, we demonstrated that this drug attenuates VEGF-C-induced VEGFR-3 phosphorylation in a dose-dependentmanner and suppresses the phosphorylation of Akt and ERK1/2. CONCLUSIONS AND IMPLICATIONS Based on these findings, we propose toluquinol as a new candidate with pharmacological potential for the treatment of lymphangiogenesis-related pathologies. Notably, its ability to suppress corneal neovascularization paves the way for applications in vascular ocular pathologies.
    • URI
      http://hdl.handle.net/10630/14679
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    2016-03-British_Journal_of_Pharmacology-accepted preprint.pdf (1.619Mb)
    Colecciones
    • BMB - Artículos

    Estadísticas

    Ver Estadísticas de uso
    Buscar en Dimension
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA